Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer.

The U.S. Surgeon General’s office released a new advisory on the link between alcohol consumption and increased risk for cancer. The advisory reports alcohol use as the third leading preventable cause...

The Prostate Cancer Clinical Trials Consortium (PCCTC) is pleased to announce its Summer 2025 internships. Opportunities are available in Data Management, Data…

You can save one, too. Donate now.

Urgent action is needed to pass the Telehealth Modernization Act before it expires, ending telemedicine on Dec. 31. This would be devastating for disabled and rural patients.

Abstract. Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine prostate cancer (NEPC) occurs in up to 15-20% of patients with castration-resistant prostate c...

Many compare it to the early days of Twitter